Integra LifeSciences Holdings Management
Management criteria checks 4/4
Integra LifeSciences Holdings' CEO is Jan De Witte, appointed in Dec 2021, has a tenure of 2.33 years. total yearly compensation is $6.39M, comprised of 13.7% salary and 86.3% bonuses, including company stock and options. directly owns 0.023% of the company’s shares, worth $531.89K. The average tenure of the management team and the board of directors is 3.8 years and 10.9 years respectively.
Key information
Jan De Witte
Chief executive officer
US$6.4m
Total compensation
| CEO salary percentage | 13.7% |
| CEO tenure | 2.3yrs |
| CEO ownership | 0.02% |
| Management average tenure | 3.8yrs |
| Board average tenure | 10.9yrs |
Recent management updates
Recent updates
Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Stalled
Feb 27
We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt
Feb 11Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Jan 14Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Price In Tune With Earnings
Dec 31Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 46% Discount?
Dec 03Does Integra LifeSciences Holdings (NASDAQ:IART) Have A Healthy Balance Sheet?
Nov 06Integra LifeSciences Holdings (NASDAQ:IART) Hasn't Managed To Accelerate Its Returns
Oct 24Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Sep 22Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 38% Discount?
Aug 15Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Hit The Brakes
Jul 03Is There Now An Opportunity In Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Jun 19Estimating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)
May 05These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well
Apr 07Integra LifeSciences Holdings (NASDAQ:IART) Is Experiencing Growth In Returns On Capital
Mar 26At US$52.61, Is It Time To Put Integra LifeSciences Holdings Corporation (NASDAQ:IART) On Your Watch List?
Mar 14Does Integra LifeSciences Holdings (NASDAQ:IART) Deserve A Spot On Your Watchlist?
Feb 27Calculating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)
Feb 02We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt
Jan 05Here's What To Make Of Integra LifeSciences Holdings' (NASDAQ:IART) Decelerating Rates Of Return
Dec 21When Should You Buy Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Dec 08Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 42% Discount?
Oct 19We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt
Oct 05Integra LifeSciences: Wide Dislocation In Fundamentals Vs. Market Value
Sep 13Is It Time To Consider Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Sep 06FDA labels recall of intracranial pressure monitors by Integra as most serious
Aug 31Integra Lifesciences voluntarily recalls pressure monitors, lowers revenue, profit guidance
Aug 24Returns At Integra LifeSciences Holdings (NASDAQ:IART) Appear To Be Weighed Down
Aug 23Integra LifeSciences founder/former CEO dies
Aug 16Integra LifeSciences Holdings GAAP EPS of $0.54 beats by $0.09, revenue of $398M beats by $2.62M
Jul 27Is There An Opportunity With Integra LifeSciences Holdings Corporation's (NASDAQ:IART) 47% Undervaluation?
Jul 20These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well
Jul 07CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$6m | US$875k | US$68m |
| Sep 30 2023 | n/a | n/a | US$101m |
| Jun 30 2023 | n/a | n/a | US$131m |
| Mar 31 2023 | n/a | n/a | US$172m |
| Dec 31 2022 | US$9m | US$850k | US$181m |
| Sep 30 2022 | n/a | n/a | US$173m |
| Jun 30 2022 | n/a | n/a | US$166m |
| Mar 31 2022 | n/a | n/a | US$157m |
| Dec 31 2021 | US$899k | US$59k | US$169m |
Compensation vs Market: Jan's total compensation ($USD6.39M) is about average for companies of similar size in the US market ($USD5.57M).
Compensation vs Earnings: Jan's compensation has been consistent with company performance over the past year.
CEO
Jan De Witte (59 yo)
2.3yrs
Tenure
US$6,388,756
Compensation
Mr. Jan De Witte has been President, Chief Executive Officer & Director of Integra LifeSciences Holdings Corporation since December 1, 2021. He had been the Chief Executive Officer at Barco NV since Septem...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 26.3yrs | US$422.52k | 2.15% $ 48.9m | |
| President | 2.3yrs | US$6.39m | 0.023% $ 531.9k | |
| Executive VP & CFO | less than a year | US$1.67m | 0.057% $ 1.3m | |
| Senior VP of Finance & Principal Accounting Officer | 6.5yrs | US$1.25m | 0.034% $ 780.2k | |
| Executive VP | 5.4yrs | US$1.62m | 0.081% $ 1.8m | |
| Executive VP & President of Tissue Technologies | 11.3yrs | US$1.42m | 0.083% $ 1.9m | |
| Executive VP & President of Codman Specialty Surgical | 3.9yrs | US$2.83m | 0.074% $ 1.7m | |
| Corporate VP of Global Operations & Supply Chain | 3.7yrs | no data | no data | |
| Vice President of Corporate Finance | no data | no data | no data | |
| Chief Information Officer & Corporate VP | no data | no data | no data | |
| Vice President of Global Corporate Communications & Public Relations | no data | no data | no data | |
| Vice President of Global Marketing | no data | no data | no data |
3.8yrs
Average Tenure
57.5yo
Average Age
Experienced Management: IART's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 26.3yrs | US$422.52k | 2.15% $ 48.9m | |
| President | 2.3yrs | US$6.39m | 0.023% $ 531.9k | |
| Independent Director | 15yrs | US$297.54k | 0.094% $ 2.1m | |
| Independent Director | 18.3yrs | US$313.80k | 0.070% $ 1.6m | |
| Independent Presiding Director | 10.9yrs | US$342.54k | 0.11% $ 2.6m | |
| Independent Director | 32.3yrs | US$306.31k | 0.078% $ 1.8m | |
| Independent Director | less than a year | US$90.68k | 0.0028% $ 64.2k | |
| Independent Director | 3yrs | US$280.05k | 0.017% $ 383.4k | |
| Independent Director | 1.8yrs | US$191.78k | 0.0095% $ 215.9k |
10.9yrs
Average Tenure
62yo
Average Age
Experienced Board: IART's board of directors are seasoned and experienced ( 10.9 years average tenure).